PRODUCT PIPELINE
CUTANEON is developing a focused portfolio of differentiated dermatology programs based on its human-centered discovery platform, proprietary insights into chemosensory skin biology, and a growing intellectual property portfolio.
Lead programs are supported by strong human ex vivo data and are being advanced toward clinical proof-of-concept with the goal of creating first-in-class therapeutic and cosmeceutical products across high-value dermatology and aesthetic indications.
Lead programs
CUT-1 – Hair Growth & REgeneration (AGA)
CUT-1 is a first-in-class program designed to stimulate hair growth and regenerate hair follicles in male pattern androgenetic alopecia, female pattern hair loss, and telogen effluvium.
The program leverages novel chemosensory signaling pathways, including TRPM5- and OR10J1-mediated mechanisms, to promote follicular activity, stem cell function, and growth factor signaling.
CUT-1 is being advanced toward clinical proof-of-concept as a potentially best-in-class regenerative therapeutic for hair growth and follicular regeneration
CUT-2 - REGEnerative aesthetic dermatology
CUT-2 is focused on developing a novel regenerative aesthetic therapeutic designed to address the underlying biological drivers of skin aging and loss of skin function.
The program targets previously underexplored chemosensory and regenerative signaling pathways, including TRPM5- and melatonin receptor-associated mechanisms, involved in structural skin regeneration, longevity biology, and tissue resilience.
Human skin models have demonstrated significant effects on established biomarkers of biological skin aging, supporting the program’s potential to establish a differentiated new category in regenerative aesthetic dermatology.
CUT-3 - unwanted hair growth control
CUT-3 is a differentiated program for the inhibition of unwanted hair growth through selective modulation of chemosensory pathways regulating hair follicle activity, including TRPM5-associated signaling mechanisms.
The program has demonstrated strong inhibitory effects in validated human ex vivo models and is being developed as a clinically relevant cosmeceutical approach for a large and underserved market.
CUTANEON has discovered that the target-specific, topical activation of either of these two TRP ion channels by their respective naturally occurring agonist(s) (CUT-4, CUT-5) greatly upregulates epidermal melanin production and activates epidermal melanocytes.
CUT-4 – prevention of chemotherapy-induced hairloss
CUT-4 is focused on protecting healthy hair follicle stem cells and tissue integrity during chemotherapy treatment, addressing one of the most distressing and insufficiently treated side effects in oncology supportive care.
The program leverages transient modulation of wild-type p53 signaling and related protective pathways to reduce apoptosis, DNA damage, and stem cell depletion in healthy follicles — without protecting tumor cells.
Despite the major clinical and psychological burden of chemotherapy-induced alopecia, there are currently no approved pharmacological therapies beyond scalp cooling approaches, representing a significant therapeutic white space and a highly differentiated market opportunity.
CUT-4 has the potential to establish a first-in-class pharmacological approach in oncology supportive care for the prevention of chemotherapy-induced alopecia.
Emerging Programs
Additional exploratory programs are being developed in areas including:
- Natural skin pigmentation (UV-free tanning)
- Chronic wound healing
- Repigmentation of gray hair
- Skin lightening
- Additional regenerative and pigmentation-related indications
- Future development priorities may be expanded selectively based on scientific progress, strategic collaborations, and investor interest.